The short version of Lipodystrophy fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-13. Anything still debated is marked as such rather than presented as settled.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
{\displaystyle {\begin{aligned}&{\frac {\beta }{\gamma }}\leq 1\Rightarrow \lim _{t\to +\infty }I(t)=0,\\[6pt]&{\frac {\beta }{\gamma }}>1\Rightarrow \lim _{t\to +\infty }I(t)=\left(1-{\frac {\gamma }{\beta }}\right)N.\end{aligned}}}
=== Journal articles and book chapters === Humphreys, Laud. (1970). "Impersonal sex in public places." Transaction, January, 1970: 10–25. Humphreys, Laud. (1971). "New styles in homosexual manliness." Transaction, March/April 1971: 38–46, 64–65. Humphreys, Laud. (1974). "Homosexual exchanges in public places." pp. 129–142 in L. Rainwater (ed.), Social problems and public policy: Deviance and liberty. Hawthorne, NY: Aldine. Humphreys, Laud. (1975). "Predicting the unpredictable: Some crime prospects for the decade." The Participant, Winter. Humphreys, Laud. (1978). "An interview with Evelyn Hooker." Alternative lifestyles: Changing patterns in marriage, family, & intimacy, Vol. 1, No. 2. Humphreys, Laud. (1979). "Being odd against all odds." pp. 238–242 in R. Fedarico (ed.), Sociology (2nd edition). Reading, MA: Addison-Wesley. Humphreys, Laud. (1979). "Exodus and identity: The emerging gay culture." pp. 134–147 in M. Levine (ed.), Gay men: The sociology of male homosexuality. New York: Harper and Row. Humphreys, Laud. (1980). "Homosexuality in perspective." Society 17(6): 84–86. Humphreys, Laud; Miller, Brian. (1980). "Keeping in touch: Maintaining contact with stigmatized subjects." pp. 212–223 in W. Shaffir, R. Stebbins, and A. Turowetz (eds.), Field Work Experience: Qualitative Approaches to Social Research. New York: St. Martin's Press. Miller, Brian; Humphreys, Laud. (1980). "Lifestyles and violence: Homosexual victims of assault and murder." Qualitative Sociology 3(3): 169–185. Goodwin, Glenn A; Humphreys, Laud. (1982).
In such isotopes, therefore, no neutron kinetic energy is needed, for all the necessary energy is supplied by absorption of any neutron, either of the slow or fast variety (the former are used in moderated nuclear reactors, and the latter are used in fast-neutron reactors, and in weapons). According to Younes and Loveland, "Actinides like 235U that fission easily following the absorption of a thermal (25 meV) neutron are called fissile, whereas those like 238U that do not easily fission when they absorb a thermal neutron are called fissionable."
The targets were said to have been Zdeněk Hřib, the mayor of Prague (capital of the Czech Republic), who was involved in renaming a square in Prague, "Pod Kaštany", where the Russian embassy is situated, to the Square of Boris Nemtsov, an opposition politician assassinated in the Kremlin in 2015; Ondřej Kolář, the mayor of Prague 6 municipal district, who was involved in removing the controversial statue to the Soviet-era Marshal Konev; and Pavel Novotný, the mayor of Prague's southwestern Řeporyje district. They all received police protection. Czech president Miloš Zeman later described the police protection of Zdeněk Hřib as an attempt by an insignificant politician to gain attention. Zeman also confused ricin with non-poisonous laxative castor oil. In 2018 and 2023 German police thwarted attempted ricin attacks, after tip-offs believed to have come from the US FBI. In 2025, security agencies in the Indian state of Gujarat arrested three Muslim men allegedly plotting a terrorist attack using ricin.
Sources: en.wikipedia.org
=== Kurdistan === Hitchens was a longtime observer of Saddam Hussein's regime, and publicly called for his removal, albeit only beginning in 1998. This led him to support the establishment of a self-governing state for the Kurds with political autonomy, if not full independence.
== Discovery == Alexander von Humboldt is sometimes said to have been the first to report the first synthetic peroxide, barium peroxide, in 1799 as a by-product of his attempts to decompose air, although this is disputed due to von Humboldt's ambiguous wording. Nineteen years later Louis Jacques Thénard recognized that this compound could be used for the preparation of a previously unknown compound, which he described as eau oxygénée ("oxygenated water") — subsequently known as hydrogen peroxide. An improved version of Thénard's process used hydrochloric acid, followed by addition of sulfuric acid to precipitate the barium sulfate byproduct. This process was used from the end of the 19th century until the middle of the 20th century. The bleaching effect of peroxides and their salts on natural dyes had been known since Thénard's experiments in the 1820s, but early attempts of industrial production of peroxides failed. The first plant producing hydrogen peroxide was built in 1873 in Berlin. The discovery of the synthesis of hydrogen peroxide by electrolysis with sulfuric acid introduced the more efficient electrochemical method. It was first commercialized in 1908 in Weißenstein, Carinthia, Austria. The anthraquinone process, which is still used, was developed during the 1930s by the German chemical manufacturer IG Farben in Ludwigshafen.
== History == References to dedifferentiation can be found as far back as 1915, where Charles Manning Child described dedifferentiation as a “return or approach to the embryonic or undifferentiated condition”. While Manning's research was about plants, it helped establish the foundation for our modern-day understanding of dedifferentiation and cell plasticity. Just as plant cells respond to injury by undergoing callus formation via dedifferentiation, some animal models dedifferentiate their cells to form blastema, which are analogous to plant calluses, after limb amputation. In the 1940s C. H. Waddington created the “Epigenetic Landscape”, a diagrammatic representation of cell fate from less differentiated to more differentiated cell types. Here, the concept of a marble moving downhill through various paths is used to represent cell decision-making and cell potency, thus visualizing how cells can take different paths of differentiation to reach a final state. Dedifferentiation would be represented by the marble moving uphill through the pathways it has already taken until it settles somewhere above the most downhill location. In our modern-day understanding of dedifferentiation, some controversies remain when defining the boundaries of its definition. Some claim that dedifferentiation is strictly limited to the same cell lineage from which it is derived. However, others say that it can be used to describe a general increase in cell potency.
=== Bone Morphogenetic Protein 1-like proteinases === In a study in 1996, Greenspan's lab showed that Bone Morphogenetic Protein 1 (BMP-1) is a protease responsible for the biosynthetic processing of the precursor protein procollagen I into type I collagen, the most abundant protein in the bodies of vertebrates. The lab also helped define the interactions of BMP1 with morphogens involved in dorsoventral patterning in early embryogenesis. They also were responsible, via various studies, for identifying and characterizing the other mammalian BMP1-like proteinases (BMP1-LPs), showing them to be a small family of proteases that activate and inactivate various growth factors, particularly a subset of the TGFβ superfamily; activate enzymes, such as lysyl oxidase, and biosynthetically process various extracellular structural macromolecules. In fact, the lab provided the preponderance of insights into biological roles of these extracellular proteases that are key to development and homeostasis and to ECM formation, and are important to formation of the cardiovascular system, wound healing, periodontal homeostasis and tooth development, and regulation of nodal Na+ channel clustering in formation of the nodes of Ranvier during neuronal development.
Journalist Dmitry Kiselyov listed the targets in the United States, which includes The Pentagon, Camp David, Fort Ritchie, McClellan Air Force Base, and Jim Creek Naval Radio Station. Kremlin spokesperson Dmitry Peskov denies the existence of the target list. On February 24, 2022, in a televised address preceding the start of the Russo-Ukrainian war (2022–present), Russian President Vladimir Putin stated that Russia "is today one of the most powerful nuclear powers in the world... No one should have any doubts that a direct attack on our country will lead to defeat and dire consequences for any potential aggressor." Later in the same speech, Putin stated: "Now a few important, very important words for those who may be tempted to intervene in ongoing events. Whoever tries to hinder us, and even more so to create threats for our country, for our people, should know that Russia's response will be immediate and will lead you to such consequences that you have never experienced in your history." On February 27, 2022, Putin publicly put his nuclear forces on alert, stating that NATO powers had made "aggressive statements". On April 14, The New York Times reported comments by CIA director William Burns, who said "potential desperation" could lead President Putin to order the use of tactical nuclear weapons.
Sources: en.wikipedia.org
=== Notch signaling === In 2015 and 2017, Garcia published articles in Science describing the first atomic-level visualizations of Notch signaling complexes. Garcia's group used directed evolution to strengthen low-affinity interactions between the receptor Notch1 and ligands Delta-like 4 (DLL4) and Jagged1 (Jag1) as a means of stabilizing the complexes for co-crystallization. Notch1-DLL4 and Notch1-Jag1 structures were determined by x-ray crystallography and revealed long, narrow binding interfaces assisted by multiple O-linked fucose and glucose modifications on Notch1. O-linked glycans are rarely observed at protein-protein interfaces, and their presence at the Notch-ligand interface explained how changes in glycosylation state influence Notch signaling activity. Garcia's 2017 publication also established that Notch-ligand interactions form catch bonds, and that Delta-like and Jagged ligands have different mechanical force thresholds for Notch receptor activation.
=== Transmission of signal === The presence of hormone or multiple hormones enables a response in the receptor, which begins a cascade of signaling. The hormone receptor interacts with different molecules to induce a variety of changes, such as an increase or decrease of nutrient sources, growth, and other metabolic functions. These signaling pathways are complex mechanisms mediated by feedback loops where different signals activate and inhibit other signals. If a signaling pathway ends with the increase in production of a nutrient, that nutrient is then a signal back to the receptor that acts as a competitive inhibitor to prevent further production. Signaling pathways regulate cells through activating or inactivating gene expression, transport of metabolites, and controlling enzymatic activity to manage growth and functions of metabolism.
=== Textiles === The 1902 edition of Encyclopædia Britannica wrote, "In no branch of applied art does the decorative genius of Japan show more attractive results than that of textile fabrics, and in none has there been more conspicuous progress during recent years. [...] Kawashima of Kyoto [...] inaugurated the departure a few years ago by copying a Gobelin, but it may safely be asserted that no Gobelin will bear comparison with the pieces now produced in Japan". Very large, colorful pictorial works were being produced in Kyoto. Embroidery had become an art form in its own right, adopting a range of pictorial techniques such as chiaroscuro and aerial perspective.
The generation of GSNO can serve as a stable and mobile NO pool which can effectively transduce NO signaling. Unlike other low molecular weight messengers that bind to and activate target cellular receptors, NO signaling is mediated by a coordinating complex between NO and transition metals or target cellular proteins, often via S-nitrosylation of cysteine residues. Studies suggest that NO metabolism has a significant role in human cardiovascular and respiratory diseases as well as in immune tolerance during organ transplantation.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.